STOCK TITAN

PVCT (PVCT) CEO Pershing converts 8% note into 339,770 common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported two non-market, derivative exercises. An 8% unsecured convertible promissory note, issued under the company’s 2025 financing, was converted into 33,977 shares of Series D-1 Convertible Preferred Stock at $2.862 per share. Each Series D-1 share is convertible into 10 common shares, and on the same date these preferred shares were converted into 339,770 shares of common stock. Following the conversion, Pershing directly owned 2,744,031 shares of common stock. The Series D-1 preferred would otherwise automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.

Positive

  • None.

Negative

  • None.
Insider Pershing Edward
Role CEO
Type Security Shares Price Value
Exercise 8% Unsecured Convertible Promissory Note 0 $0.00 --
Exercise Series D-1 Convertible Preferred Stock 33,977 $0.00 --
Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct); Series D-1 Convertible Preferred Stock — 2,744,031 shares (Direct)
Footnotes (1)
  1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On April 04, 2026, the 2025 Note was converted into 33,977 shares of Series D-1 Preferred Stock.
Note conversion price $2.862 per share Conversion of 8% unsecured convertible promissory note into Series D-1 preferred
Series D-1 shares received 33,977 shares Shares of Series D-1 Convertible Preferred Stock from note conversion
Common shares from preferred 339,770 shares Common stock received from converting 33,977 Series D-1 preferred shares
Post-transaction common holdings 2,744,031 shares Edward Pershing’s direct PVCT common stock after conversions
Series D-1 conversion ratio 10 common per preferred share Each Series D-1 Convertible Preferred share converts into 10 common shares
Automatic preferred conversion date December 31, 2028 Automatic conversion date for Series D-1 preferred if not earlier converted
8% unsecured convertible promissory note financial
"The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note"
Series D-1 Convertible Preferred Stock financial
"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"
automatic conversion financial
"The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028"
Certificate of Designation regulatory
"in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock"
A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.
2025 Financing financial
"The 2025 Note was issued pursuant to the Issuer's 2025 Financing"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pershing Edward

(Last)(First)(Middle)
800 S. GAY STREET,
SUITE 1610

(Street)
KNOXVILLE TENNESSEE 37929

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
8% Unsecured Convertible Promissory Note$2.86204/04/2026M$90,00004/04/202504/04/2026Series D-1 Convertible Preferred Stock(3)(4)33,977$0$1,145,000D
Series D-1 Convertible Preferred Stock(1)04/04/2026M33,97704/04/2026 (2)Common Stock339,770$02,744,031D
Explanation of Responses:
1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
4. On April 04, 2026, the 2025 Note was converted into 33,977 shares of Series D-1 Preferred Stock.
/s/ Edward Pershing04/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PVCT CEO Edward Pershing report on this Form 4?

Edward Pershing reported exercising derivative securities, not buying on the open market. An 8% unsecured convertible promissory note converted into 33,977 Series D-1 preferred shares, which then converted into 339,770 common shares, increasing his direct common stock holdings.

How many PVCT common shares did Edward Pershing receive from these conversions?

The conversions resulted in 339,770 new common shares for Edward Pershing. These came from 33,977 Series D-1 Convertible Preferred shares, each convertible into 10 common shares, and brought his direct common stock ownership to 2,744,031 shares after the transactions.

What was the conversion price on the PVCT 8% unsecured convertible promissory note?

The 8% unsecured convertible promissory note converted into Series D-1 Convertible Preferred Stock at $2.862 per share. This automatic conversion occurred 12 months after the note’s issue date, as described, and produced 33,977 Series D-1 preferred shares for Edward Pershing.

What is the conversion ratio of PVCT’s Series D-1 Convertible Preferred Stock?

Each share of Series D-1 Convertible Preferred Stock converts into 10 shares of common stock. In this filing, 33,977 Series D-1 shares converted into 339,770 common shares, consistent with that 10-to-1 conversion ratio disclosed in the transaction footnotes.

When would PVCT’s Series D-1 preferred automatically convert if not converted earlier?

The Series D-1 Convertible Preferred Stock automatically converts into common stock on December 31, 2028, unless converted earlier under its terms. In this case, Edward Pershing’s Series D-1 shares were converted earlier, on April 4, 2026, into common shares.

How many PVCT common shares did Edward Pershing hold after these Form 4 transactions?

After the reported derivative exercises and conversions, Edward Pershing directly held 2,744,031 shares of PVCT common stock. This figure reflects his position immediately following the conversion of 33,977 Series D-1 preferred shares into 339,770 common shares.